Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Gerald Heatley"'
Autor:
Mandeep R. Mehra, Aditi Nayak, Alanna A. Morris, David E. Lanfear, Hassan Nemeh, Sapna Desai, Aditya Bansal, Cesar Guerrero-Miranda, Shelley Hall, Joseph C. Cleveland, Daniel J. Goldstein, Nir Uriel, Leway Chen, Stephen Bailey, Anelechi Anyanwu, Gerald Heatley, Joyce Chuang, Jerry D. Estep
Publikováno v:
JACC: Heart Failure. 10:948-959
BACKGROUND: Clinical trials inform on average efficacy, but individualized risk assessments for outcome prediction are important in guiding treatment implementation. OBJECTIVES: The authors developed and validated a patient-specific risk score to pre
Autor:
Francis D. Pagani, Jason N. Katz, Ulrich P. Jorde, Mandeep R. Mehra, Nir Uriel, Poornima Sood, Finn Gustafsson, Jean M. Connors, Ivan Netuka, Gerald Heatley, D. Crandall
Publikováno v:
European Journal of Heart Failure
Mehra, M R, Crandall, D L, Gustafsson, F, Jorde, U P, Katz, J N, Netuka, I, Uriel, N, Connors, J M, Sood, P, Heatley, G & Pagani, F D 2021, ' Aspirin and left ventricular assist devices : rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial ', European Journal of Heart Failure, vol. 23, no. 7, pp. 1226-1237 . https://doi.org/10.1002/ejhf.2275
Mehra, M R, Crandall, D L, Gustafsson, F, Jorde, U P, Katz, J N, Netuka, I, Uriel, N, Connors, J M, Sood, P, Heatley, G & Pagani, F D 2021, ' Aspirin and left ventricular assist devices : rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial ', European Journal of Heart Failure, vol. 23, no. 7, pp. 1226-1237 . https://doi.org/10.1002/ejhf.2275
Aims Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous‐flow pumps which have substantially improved long‐term outcomes and quality of life. Contemporary LVAD therap
Autor:
Ranjit John, Manreet K. Kanwar, Joseph C. Cleveland, Nir Uriel, Yoshifumi Naka, Christopher Salerno, Douglas Horstmanshof, Shelley A. Hall, Jennifer A. Cowger, Gerald Heatley, Sami I. Somo, Mandeep R. Mehra
Publikováno v:
The Journal of thoracic and cardiovascular surgery.
Correction of valvular disease is often undertaken during left ventricular assist device (LVAD) implantation with uncertain benefit. We analyzed clinical outcomes with HeartMate 3 (HM3; Abbott) LVAD implantation in those with various concurrent valve
Autor:
Jacob Lavee, Jens Garbade, Diyar Saeed, Finn Gustafsson, Evgenij V. Potapov, Michael Berchtold-Herz, Jan D. Schmitto, Carlo Gazzola, Daniel Zimpfer, Steven M. Shaw, Michiel Morshuis, Gerald Heatley, Yuriy Pya
Publikováno v:
European heart journal. 41(39)
Aims The ELEVATE Registry was designed to study long-term outcomes with the Heartmate 3 (HM3), a fully magnetically levitated centrifugal ventricular assist device, in a real-world population following CE-mark approval. Methods and results A total of
Autor:
Steven M. Shaw, Jacob Lavee, Michiel Morshuis, Jens Garbade, Elevate investigators, Carlo Gazzola, Evgenij V. Potapov, Diyar Saeed, Michael Berchtold-Herz, Finn Gustafsson, Yuriy Pya, Jan D. Schmitto, Gerald Heatley, Daniel Zimpfer
Publikováno v:
SSRN Electronic Journal.
Background: The ELEVATE Registry was designed to study long-term outcomes with the Heartmate 3 (HM3), a fully magnetically levitated centrifugal ventricular assist device, in a real-world population following CE-mark approval. Methods: A total of 540
Autor:
Gregory A. Ewald, Eric Skipper, Carmelo A. Milano, Yoshifumi Naka, John B. O'Connell, Joseph C. Cleveland, Ulrich P. Jorde, Poornima Sood, James W. Long, Mary Norine Walsh, Akinobu Itoh, Jerry D. Estep, Chetan B. Patel, Christopher T. Salerno, Douglas A. Horstmanshof, David A. Dean, Gabriel Sayer, Valluvan Jeevanandam, Arun Krishnamoorthy, William Cotts, Mandeep R. Mehra, Sanjeev K. Gulati, Nir Uriel, Antone Tatooles, Daniel J. Goldstein, Brian A. Bruckner, Melana Yuzefpolskaya, Gerald Heatley
Publikováno v:
The New England journal of medicine. 378(15)
In an early analysis of this trial, use of a magnetically levitated centrifugal continuous-flow circulatory pump was found to improve clinical outcomes, as compared with a mechanical-bearing axial continuous-flow pump, at 6 months in patients with ad
Autor:
Axel Haverich, Nir Uriel, Jan D. Schmitto, Poornima Sood, Eric Kruse, Dominik Berliner, Sirtaz Adatya, Gerald Heatley, Michael Želízko, Ales Herman, Jiří Malý, Johann Bauersachs, Daniel Rodgers, Ivan Netuka
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 36(1)
Background The HeartMate 3 (HM3) is a Conformitee Europeenne (CE) mark–approved left ventricular assist device (LVAD) with a fully magnetically levitated rotor with features consisting of a wide range of operational speeds, wide flow paths and an a
Autor:
Stuart D. Russell, Ranjit John, Jeffrey J. Teuteberg, O. Howard Frazier, Gerald Heatley, David J. Farrar, Francis D. Pagani, Mark S. Slaughter, Nader Moazami, Andrew J. Boyle
Publikováno v:
The Journal of Heart and Lung Transplantation. 28:881-887
The HeartMate II (Thoratec, Pleasanton, CA) is an effective bridge to transplantation (BTT) but requires anti-coagulation with warfarin and aspirin. We evaluated the risk of thromboembolism and hemorrhage related to the degree of anti-coagulation as
Autor:
Dzifa Dordunoo, T. Yanssens, Stuart D. Russell, David J. Farrar, David S. Feldman, Y. Naka, Brian E. Jaski, Kathy A. Idrissi, Gerald Heatley, Lalig Koundakjian, Keith D. Aaronson, Susan Wright, Ralph J. Petrucci, Suzanne Chillcott
Publikováno v:
The Journal of Heart and Lung Transplantation. 28:542-549
Neurocognitive (NC) changes in heart failure patients receiving left ventricular assist devices (LVADs) are not well understood. The purpose of this study was to document changes in the cognitive performance of patients with the continuous-flow Heart
Autor:
Satoshi Furukawa, Alfred J. Tector, Walter P. Dembitsky, Laura Damme, Gerald Heatley, Nuala S. Ronan, Alan D. Weinberg, William Piccione, James W. Long, Annetine C. Gelijns, Soon J. Park, William L. Holman, Victor Poirier, Alan J. Moskowitz
Publikováno v:
The Annals of Thoracic Surgery. 78:2123-2130
Background Left ventricular assist device (LVAD) failure and malfunction rates are critical gauges for establishing LVADs as a long-term therapy for end-stage heart failure patients. These device performance measures, however, have been inadequately